How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/j.it.2018.10.009.

Abstract

Anti-CTLA-4 antibodies can induce lasting protection for some melanoma patients. However, their therapeutic potential is limited by significant immunotherapy-related adverse effects (irAE). Here, we argue that the therapeutic effect may be based on an agonist activity that is fundamentally distinct, and can be therapeutically differentiated, from the antagonist activity responsible for irAE.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / immunology*
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / immunology*

Substances

  • Antibodies, Monoclonal
  • CTLA-4 Antigen